Noshchenko Andriy, Hoffecker Lilian, Lindley Emily M, Burger Evalina L, Cain Christopher M J, Patel Vikas V
*Department of Orthopedics †Health Sciences Library, University of Colorado Anschutz Medical Campus, Aurora, CO.
J Spinal Disord Tech. 2014 May;27(3):117-35. doi: 10.1097/01.bsd.0000446752.34233.ca.
Systematic review with meta-analysis.
To compare the perioperative and long-term postoperative effectiveness of bone morphogenetic protein (BMP) for lumbar arthrodesis in skeletally mature adults with degenerative disk disease (DDD) to that of the current golden standard treatment, iliac crest autologous bone graft (ICBG).
The treatment efficacy of lumbar arthrodesis in DDD is a complex clinical and economic issue for patients and health care providers.
Comprehensive electronic literature search was performed using following databases: Ovid MEDLINE; Embase; Cochrane Library; Central Register of Controlled Trials (CENTRAL); Database of Abstracts of Reviews of Effects; Methodology Register; Technology Assessment Database; and Economic Evaluation Database. The full year ranges of each database until May of 2012 were included.
Eight randomized controlled clinical trials of 383 citations were selected. The included studies involved 1138 participants. The pooled 2-year postoperative clinical outcomes were equivalent in BMP and ICBG groups, and exceeded minimum clinically important differences for Oswestry Disability Index, SF-36 (physical scale), and numeric rating scale (back pain). ICBG was associated with increased pain and complications at the donor site (P<0.01). The pooled average operative time was 21 minutes less in BMP versus ICBG (P<0.001). The pooled rate of additional surgical treatment was 2 times less in the BMP than in the ICBG groups (P=0.006). The pooled risk of nonunion at 24-month follow-up was 2 times less in the BMP than in the ICBG groups (P=0.037), however, this effect was likely biased.
BMP, in particular rhBMP-2, is a good alternative to autogenous bone graft, especially in cases when harvesting of autologous bone is contraindicated or undesirable, operation time is limited, and there are no contraindications for BMP use.However, the current study did not reveal evidence robust enough to develop strong medical recommendations concerning BMP use for lumbar arthrodesis in degenerative disk disease.
系统评价与荟萃分析。
比较骨形态发生蛋白(BMP)与目前的金标准治疗方法——髂嵴自体骨移植(ICBG)在骨骼成熟的退行性椎间盘疾病(DDD)成年患者中进行腰椎融合术的围手术期及术后长期疗效。
腰椎融合术治疗DDD的疗效对于患者和医疗服务提供者而言是一个复杂的临床和经济问题。
使用以下数据库进行全面的电子文献检索:Ovid MEDLINE;Embase;Cochrane图书馆;对照试验中央注册库(CENTRAL);疗效评价摘要数据库;方法学注册库;技术评估数据库;以及经济评估数据库。纳入了各数据库截至2012年5月的全年范围数据。
从383篇文献中筛选出8项随机对照临床试验。纳入研究涉及1138名参与者。BMP组和ICBG组术后2年的综合临床结局相当,并且超过了Oswestry功能障碍指数、SF - 36(身体维度)和数字评分量表(背痛)的最小临床重要差异。ICBG与供区疼痛和并发症增加相关(P<0.01)。BMP组的合并平均手术时间比ICBG组少21分钟(P<0.001)。BMP组额外手术治疗的合并发生率比ICBG组低2倍(P = 0.006)。在24个月随访时,BMP组骨不连的合并风险比ICBG组低2倍(P = 0.037),然而,这种效应可能存在偏倚。
BMP,尤其是重组人骨形态发生蛋白 - 2,是自体骨移植的良好替代物,特别是在自体骨采集禁忌或不可取、手术时间有限且无BMP使用禁忌的情况下。然而,目前的研究并未揭示出足够有力的证据来制定关于BMP用于退行性椎间盘疾病腰椎融合术的强有力医学建议。